Censoring in trials testing immunotherapy in advanced cancers. A systematic review and a meta-research study

View Full Paper

Ask AI

Bookmark

Censoring rates were significantly higher in control arms at the start of the trials, indicating possible bias.
For progression free survival, the censoring rate was 8.19% in control and 4.92% in experimental groups at T1.
Analysis of 140 trials revealed that many did not report censoring data, highlighting a gap in transparency.
Higher rates of censoring were found in open-label trials compared to double-blinded studies, suggesting design influences.

Discussion

No takes yet. Share an insight, caveat, or question.

Systematic review found higher censoring rates in control versus experimental arms in trials of immune checkpoint inhibitors.

Vitale et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark